Minor	minor	O	O	O	O
neurological	neurological	O	O	OTHERS	I
dysfunction	dysfunction	O	O	OTHERS	I
,	,	O	O	O	O
cognitive	cognitive	O	O	O	O
development	development	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
somatic	somatic	O	O	O	O
development	development	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
age	age	O	O	O	O
of	of	O	O	O	O
3	3	O	O	O	O
to	to	O	O	O	O
7	7	O	O	O	O
years	years	O	O	O	O
after	after	O	O	O	O
dexamethasone	dexamethasone	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
in	in	O	O	O	O
very-low	very-low	O	O	O	O
birth-weight	birth-weight	O	O	O	O
infants	infants	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
objective	objective	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
to	to	O	O	O	O
assess	assess	O	O	O	O
minor	minor	O	O	O	O
neurological	neurological	O	O	OTHERS	I
dysfunction	dysfunction	O	O	OTHERS	I
,	,	O	O	O	O
cognitive	cognitive	O	O	O	O
development	development	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
somatic	somatic	O	O	O	O
development	development	O	O	O	O
after	after	O	O	O	O
dexamethasone	dexamethasone	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
in	in	O	O	O	O
very-low-birthweight	very-low-birthweight	O	O	O	O
infants	infants	O	O	O	O
.	.	O	O	O	O

Thirty-three	thirty-three	O	O	O	O
children	children	O	O	O	O
after	after	O	O	O	O
dexamethasone	dexamethasone	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
were	were	O	O	O	O
matched	matched	O	O	O	O
to	to	O	O	O	O
33	33	O	O	O	O
children	children	O	O	O	O
without	without	O	O	O	O
dexamethasone	dexamethasone	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
.	.	O	O	O	O

Data	data	O	O	O	O
were	were	O	O	O	O
assessed	assessed	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
age	age	O	O	O	O
of	of	O	O	O	O
3	3	O	O	O	O
-	-	O	O	O	O
7	7	O	O	O	O
years	years	O	O	O	O
.	.	O	O	O	O

Dexamethasone	dexamethasone	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
started	started	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
7th	7th	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
28th	28th	O	O	O	O
day	day	O	O	O	O
of	of	O	O	O	O
life	life	O	O	O	O
over	over	O	O	O	O
7	7	O	O	O	O
days	days	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
total	total	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
2.35	2.35	O	O	O	O
mg/kg/day	mg/kg/day	O	O	O	O
.	.	O	O	O	O

Exclusion	exclusion	O	O	O	O
criteria	criteria	O	O	O	O
were	were	O	O	O	O
asphyxia	asphyxia	O	O	OTHERS	I
,	,	O	O	O	O
malformations	malformations	O	O	OTHERS	I
,	,	O	O	O	O
major	major	O	O	O	O
surgical	surgical	O	O	O	O
interventions	interventions	O	O	O	O
,	,	O	O	O	O
small	small	O	O	O	O
for	for	O	O	O	O
gestational	gestational	O	O	O	O
age	age	O	O	O	O
,	,	O	O	O	O
intraventricular	intraventricular	O	O	O	O
haemorrhage	haemorrhage	O	O	OTHERS	I
grades	grades	O	O	O	O
III	iii	O	O	O	O
and	and	O	O	O	O
IV	iv	O	O	O	O
,	,	O	O	O	O
periventricular	periventricular	O	O	OTHERS	I
leukomalacia	leukomalacia	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
severe	severe	O	O	O	O
psychomotor	psychomotor	O	O	OTHERS	I
retardation	retardation	O	O	OTHERS	I
.	.	O	O	O	O

Each	each	O	O	O	O
child	child	O	O	O	O
was	was	O	O	O	O
examined	examined	O	O	O	O
by	by	O	O	O	O
a	a	O	O	O	O
neuropediatrician	neuropediatrician	O	O	O	O
for	for	O	O	O	O
minor	minor	O	O	O	O
neurological	neurological	O	O	OTHERS	I
dysfunctions	dysfunctions	O	O	OTHERS	I
and	and	O	O	O	O
tested	tested	O	O	O	O
by	by	O	O	O	O
a	a	O	O	O	O
psychologist	psychologist	O	O	O	O
for	for	O	O	O	O
cognitive	cognitive	O	O	O	O
development	development	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
Kaufman	kaufman	O	O	O	O
Assessment	assessment	O	O	O	O
Battery	battery	O	O	O	O
for	for	O	O	O	O
Children	children	O	O	O	O
and	and	O	O	O	O
a	a	O	O	O	O
Draw-a-Man	draw-a-man	O	O	O	O
Test	test	O	O	O	O
.	.	O	O	O	O

There	there	O	O	O	O
were	were	O	O	O	O
no	no	O	O	O	O
differences	differences	O	O	O	O
in	in	O	O	O	O
demographic	demographic	O	O	O	O
data	data	O	O	O	O
,	,	O	O	O	O
growth	growth	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
socio-economic	socio-economic	O	O	O	O
status	status	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
two	two	O	O	O	O
groups	groups	O	O	O	O
.	.	O	O	O	O

Fine	fine	O	O	O	O
motor	motor	O	O	O	O
skills	skills	O	O	O	O
and	and	O	O	O	O
gross	gross	O	O	O	O
motor	motor	O	O	O	O
function	function	O	O	O	O
were	were	O	O	O	O
significantly	significantly	O	O	O	O
better	better	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
control	control	O	O	O	O
group	group	O	O	O	O
(	(	O	O	O	O
p<0.01	p<0.01	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
Draw-a-Man	draw-a-man	O	O	O	O
Test	test	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
control	control	O	O	O	O
group	group	O	O	O	O
showed	showed	O	O	O	O
better	better	O	O	O	O
results	results	O	O	O	O
(	(	O	O	O	O
p<0.001	p<0.001	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

There	there	O	O	O	O
were	were	O	O	O	O
no	no	O	O	O	O
differences	differences	O	O	O	O
in	in	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
speech	speech	O	O	O	O
,	,	O	O	O	O
social	social	O	O	O	O
development	development	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
Kaufman	kaufman	O	O	O	O
Assessment	assessment	O	O	O	O
Battery	battery	O	O	O	O
for	for	O	O	O	O
Children	children	O	O	O	O
.	.	O	O	O	O

After	after	O	O	O	O
dexamethasone	dexamethasone	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
,	,	O	O	O	O
children	children	O	O	O	O
showed	showed	O	O	O	O
a	a	O	O	O	O
higher	higher	O	O	O	O
rate	rate	O	O	O	O
of	of	O	O	O	O
minor	minor	O	O	O	O
neurological	neurological	O	O	OTHERS	I
dysfunctions	dysfunctions	O	O	OTHERS	I
.	.	O	O	O	O

Neurological	neurological	O	O	O	O
development	development	O	O	O	O
was	was	O	O	O	O
affected	affected	O	O	O	O
even	even	O	O	O	O
without	without	O	O	O	O
neurological	neurological	O	O	O	O
diagnosis	diagnosis	O	O	O	O
.	.	O	O	O	O

Further	further	O	O	O	O
long-term	long-term	O	O	O	O
follow-up	follow-up	O	O	O	O
studies	studies	O	O	O	O
will	will	O	O	O	O
be	be	O	O	O	O
necessary	necessary	O	O	O	O
to	to	O	O	O	O
fully	fully	O	O	O	O
evaluate	evaluate	O	O	O	O
the	the	O	O	O	O
impact	impact	O	O	O	O
of	of	O	O	O	O
dexamethasone	dexamethasone	CHEMICALS	O	OTHERS	I
on	on	O	O	O	O
neurological	neurological	O	O	O	O
and	and	O	O	O	O
cognitive	cognitive	O	O	O	O
development	development	O	O	O	O
.	.	O	O	O	O

